🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT03516617Phase 23 sites📍 Scottsdale📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Acalabrutinib, Laboratory Biomarker Analysis, Obinutuzumab, Patient Observation, Quality-of-Life Assessment A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) NCT06136559Phase 3206 sites📍 Mobile📍 Gilbert📍 Phoenix Merck Sharp & Dohme LLC · Tests: Nemtabrutinib, Ibrutinib, Acalabrutinib A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250Phase 1, Phase 231 sites📍 La Jolla📍 Boston📍 Rochester AstraZeneca · Tests: AZD5492 A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL NCT07609823Phase 21 site📍 Nanjing Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Lacutoclax A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) NCT07221500Phase 240 sites📍 Phoenix📍 Duarte📍 Los Angeles Nurix Therapeutics, Inc. · Tests: NX-5948 Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL NCT05147467Phase 211 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG2575 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study NCT04269902Phase 3633 sites📍 Birmingham📍 Anchorage📍 Anchorage National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT05091424Phase 131 sites📍 Rochester📍 New York📍 Columbus Hoffmann-La Roche · Tests: Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies NCT06191887Phase 11 site📍 Jacksonville Mayo Clinic · Tests: Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: HSCT with TBI Regimen, HSCT with Non-TBI Regimen Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT03666000Phase 115 sites📍 Tampa📍 Atlanta📍 Atlanta Imugene Limited · Tests: Azer-cel, Fludarabine, Cyclophosphamide, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma NCT06916767Phase 11 site📍 Cleveland Paolo Caimi, MD · Tests: BAFF CAR-T, Obinutuzumab, Cyclophosphamide, Fludarabine Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial NCT04941716Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Acalabrutinib, Venetoclax, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL NCT04215809Phase 19 sites📍 Duarte📍 Jacksonville📍 Boston Ascentage Pharma Group Inc. · Tests: Lisaftoclax Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) NCT07509151Phase 344 sites📍 La Jolla📍 Denver📍 New Haven AstraZeneca · Tests: Surovatamig A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06588478Phase 2131 sites📍 Chandler📍 Duarte📍 Irvine Loxo Oncology, Inc. · Tests: Pirtobrutinib Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma NCT07030400n/a1 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Bruton's tyrosine kinase inhibitor, B-Cell Lymphoma 2 Protein Inhibitor Study of Epcoritamab as a Consolidation Therapy in CLL/SLL NCT07108998Phase 21 site📍 Cincinnati Zulfa Omer · Tests: Epcoritamab A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) NCT06520098Phase 24 sites📍 San Francisco📍 Kansas City📍 Durham VA Office of Research and Development · Tests: Venetoclax, Ibrutinib, Acalabrutinib, Zanubrutinib Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. NCT04771572Phase 18 sites📍 Chicago📍 Boston📍 Chapel Hill Newave Pharmaceutical Inc · Tests: LP-118 AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363Phase 113 sites📍 Orange📍 Miami Beach📍 Tampa Carna Biosciences, Inc. · Tests: Docirbrutinib Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL NCT05963217Phase 11 site📍 Toronto University Health Network, Toronto · Tests: TBI-2001, Cyclophosphamide, Fludarabine A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma NCT06876662Phase 436 sites📍 Miami📍 Sarasota📍 Atlanta Eli Lilly and Company · Tests: Pirtobrutinib A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) NCT07154264Phase 215 sites📍 Hefei📍 Beijing📍 Guangzhou Dizal Pharmaceuticals · Tests: DZD8586, Venetoclax Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL NCT05791409Phase 1, Phase 229 sites📍 Melbourne📍 Melbourne📍 Melbourne Stichting Hemato-Oncologie voor Volwassenen Nederland · Tests: Epcoritamab, Venetoclax ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL NCT07342478Phase 36 sites📍 Skokie📍 Bethesda📍 Las Vegas Newave Pharmaceutical Inc · Tests: Rocbrutinib, Pirtobrutinib DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) NCT06539182Phase 217 sites📍 Hefei📍 Beijing📍 Beijing Dizal Pharmaceuticals · Tests: DZD8586, DZD8586, DZD8586 A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) NCT06943872Phase 3195 sites📍 Laguna Hills📍 Orange📍 Palo Alto BeOne Medicines · Tests: Sonrotoclax, Obinutuzumab, Rituximab, Venetoclax
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy